Royal Bank of Canada
CVKD icon

Royal Bank of Canada’s Cadrenal Therapeutics CVKD Stock Holding History

Royal Bank of Canada’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed – – 6941
2024
Q3 		$0 Buy
+25
New +$201 ﹤0.01% 6950

Other funds holding CVKD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
RS
R Squared Central, Hong Kong $182M AUM 18.52% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CWA
Carolina Wealth Advisors Myrtle Beach, South Carolina $255M AUM 17.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's CVKD Position: Q4 2024 in Review

Royal Bank of Canada sold out of Cadrenal Therapeutics (CVKD) in Q4 2024, closing a stake of 25 shares.

Royal Bank of Canada first reported a position in CVKD in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 10 funds tracked by Wall St. Rank hold CVKD as of Q4 2024.

  • Royal Bank of Canada reported no remaining Cadrenal Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 25 Cadrenal Therapeutics shares in Q4 2024.
  • Royal Bank of Canada first reported a position in Cadrenal Therapeutics in Q3 2024 and held it in 1 quarter.
  • Royal Bank of Canada's Cadrenal Therapeutics position peaked at $0 in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.